Oric Pharmaceuticals(DE:4TZ)
€7.96+0.27 (+6.16%)
DE:4TZ
Oric Pharmaceuticals financials statements
€7.96
At close:+0.27 (+6.16%)
Oric Pharmaceuticals (4TZ) Ratios
1 Followers
Oric Pharmaceuticals Ratios
DE:4TZ's free cash flow for Q2 2026 was $-31.96M. For the 2026 fiscal year, DE:4TZ's free cash flow was decreased by $-356.00K and operating cash flow was $-31.61M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.13 | 10.56 | 10.39 | 13.68 | 15.87 |
| Quick Ratio | 14.13 | 10.56 | 10.39 | 13.68 | 15.87 |
| Cash Ratio | 2.24 | 2.39 | 1.14 | 4.34 | 14.92 |
| Solvency Ratio | -5.23 | -4.09 | -3.26 | -3.15 | -3.03 |
| Operating Cash Flow Ratio | -5.44 | -4.53 | -4.19 | -4.88 | -3.93 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -31.14 | -28.26 | 0.00 |
| Net Current Asset Value | $ 263.94M | $ 231.23M | $ 182.00M | $ 182.45M | $ 214.86M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.04 | 0.05 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.05 | 0.05 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.04 | 0.05 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.06 | 1.13 | 1.14 | 1.13 | 1.09 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -39.88 | -16.18 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -34.69 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.05 | 0.20 | 0.37 | 0.05 |
| Net Debt to EBITDA | 0.33 | 0.44 | 0.12 | 0.64 | 2.87 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 90.53% | 89.47% | 90.90% | 97.12% | 99.80% |
| Return on Assets (ROA) | -31.66% | -46.64% | -39.54% | -35.60% | -26.36% |
| Return on Equity (ROE) | -33.68% | -52.59% | -44.94% | -40.08% | -28.84% |
| Return on Capital Employed (ROCE) | -36.81% | -57.32% | -47.30% | -39.05% | -27.82% |
| Return on Invested Capital (ROIC) | -36.50% | -56.60% | -46.75% | -38.62% | -27.63% |
| Return on Tangible Assets | -31.66% | -46.64% | -39.54% | -35.60% | -26.36% |
| Earnings Yield | -18.03% | -22.72% | -21.27% | -38.16% | -14.11% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.32 | 0.72 | 1.09 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1144.07 | -510.41 | -333.88 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1144.07 | 510.41 | 333.88 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.26 | -1.62 | -1.67 | -1.89 | -1.57 |
| Free Cash Flow Per Share | -1.27 | -1.63 | -1.68 | -1.95 | -1.59 |
| Dividend Paid and CapEx Coverage Ratio | -155.86 | -94.83 | -100.93 | -36.16 | -63.41 |
| Capital Expenditure Coverage Ratio | -155.86 | -94.83 | -100.93 | -36.16 | -63.41 |
| Operating Cash Flow Coverage Ratio | -33.32 | -35.39 | -8.39 | -6.21 | -30.91 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -15.55% | -20.23% | -18.28% | -33.06% | -10.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.56 | -4.41 | -4.70 | -2.62 | -7.09 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.87 | 2.31 | 2.11 | 1.05 | 2.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.43 | -4.94 | -5.47 | -3.02 | -9.22 |
| Price-to-Operating Cash Flow Ratio | -6.47 | -4.99 | -5.52 | -3.11 | -9.37 |
| Price-to-Earnings Growth (PEG) Ratio | 0.28 | 0.66 | 0.36 | -0.30 | 0.18 |
| Enterprise Value Multiple | -5.27 | -4.00 | -4.19 | -2.08 | -4.28 |
| Enterprise Value | 675.81M | 506.47M | 460.17M | 178.83M | 333.84M |
| EV to EBITDA | -5.27 | -4.00 | -4.19 | -2.08 | -4.28 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.05 | -4.45 | -5.32 | -2.32 | -5.52 |
| EV to Operating Cash Flow | -6.09 | -4.50 | -5.37 | -2.38 | -5.61 |
| Tangible Book Value Per Share | 4.38 | 3.49 | 4.36 | 5.61 | 7.19 |
| Shareholders’ Equity Per Share | 4.38 | 3.49 | 4.36 | 5.61 | 7.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.91 | 1.03 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.86 | 0.88 | 0.85 | 0.84 | 0.76 |
Currency in USD
